CN110167543A - 包含对乙酰氨基酚和磺烷基醚环糊精的制剂 - Google Patents

包含对乙酰氨基酚和磺烷基醚环糊精的制剂 Download PDF

Info

Publication number
CN110167543A
CN110167543A CN201780071033.7A CN201780071033A CN110167543A CN 110167543 A CN110167543 A CN 110167543A CN 201780071033 A CN201780071033 A CN 201780071033A CN 110167543 A CN110167543 A CN 110167543A
Authority
CN
China
Prior art keywords
preparation
sulfoalkyl ether
paracetamol
ether cyclodextrin
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780071033.7A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·D·皮普金
格洛德·L·莫舍
罗杰·拉耶夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cydex Pharmaceuticals Inc
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Priority to CN202310814285.1A priority Critical patent/CN116869983A/zh
Publication of CN110167543A publication Critical patent/CN110167543A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CN201780071033.7A 2016-09-16 2017-09-15 包含对乙酰氨基酚和磺烷基醚环糊精的制剂 Pending CN110167543A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310814285.1A CN116869983A (zh) 2016-09-16 2017-09-15 包含对乙酰氨基酚和磺烷基醚环糊精的制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395794P 2016-09-16 2016-09-16
US62/395,794 2016-09-16
PCT/US2017/051919 WO2018053358A1 (en) 2016-09-16 2017-09-15 Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310814285.1A Division CN116869983A (zh) 2016-09-16 2017-09-15 包含对乙酰氨基酚和磺烷基醚环糊精的制剂

Publications (1)

Publication Number Publication Date
CN110167543A true CN110167543A (zh) 2019-08-23

Family

ID=61619250

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780071033.7A Pending CN110167543A (zh) 2016-09-16 2017-09-15 包含对乙酰氨基酚和磺烷基醚环糊精的制剂
CN202310814285.1A Pending CN116869983A (zh) 2016-09-16 2017-09-15 包含对乙酰氨基酚和磺烷基醚环糊精的制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310814285.1A Pending CN116869983A (zh) 2016-09-16 2017-09-15 包含对乙酰氨基酚和磺烷基醚环糊精的制剂

Country Status (9)

Country Link
US (1) US20190255000A1 (enExample)
EP (1) EP3512511A4 (enExample)
JP (3) JP7181185B2 (enExample)
KR (2) KR20240005122A (enExample)
CN (2) CN110167543A (enExample)
AU (3) AU2017326519B2 (enExample)
CA (1) CA3036989A1 (enExample)
MX (2) MX2019002976A (enExample)
WO (1) WO2018053358A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119233815A (zh) * 2022-05-20 2024-12-31 株式会社大赛璐 液态医药组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277546A1 (en) * 2009-07-23 2011-01-26 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable ready to use injectable paracetamol formulation
WO2012037117A1 (en) * 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
CN104704007A (zh) * 2012-02-28 2015-06-10 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20110015273A1 (en) * 2008-01-17 2011-01-20 Rajnarayana Kandhagatla Stable pharmaceutical aqueous compositions
CN102871994B (zh) * 2012-09-29 2015-07-29 中国科学院大连化学物理研究所 氟比洛芬对乙酰氨基酚酯环糊精包合物及其制备方法
BR102014005885B1 (pt) * 2014-03-13 2021-04-13 Biotec Biológica Indústria Farmacêutica Ltda E.P.P Formulação farmacêutica líquida injetável estável de paracetamol em bolsa plástica pronta para uso
SMT202100404T1 (it) * 2016-02-04 2021-09-14 Czap Research And Development Llc Veicoli di complessi di inclusione di ciclodestrine stratificati e rilascio controllato

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277546A1 (en) * 2009-07-23 2011-01-26 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable ready to use injectable paracetamol formulation
WO2012037117A1 (en) * 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
CN104704007A (zh) * 2012-02-28 2015-06-10 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法

Also Published As

Publication number Publication date
WO2018053358A1 (en) 2018-03-22
EP3512511A1 (en) 2019-07-24
US20190255000A1 (en) 2019-08-22
KR20190065296A (ko) 2019-06-11
JP2024051102A (ja) 2024-04-10
MX2019002976A (es) 2019-07-10
AU2025204233A1 (en) 2025-06-26
JP2022140780A (ja) 2022-09-27
EP3512511A4 (en) 2020-05-20
JP2019532927A (ja) 2019-11-14
MX2023003761A (es) 2023-04-26
AU2023203660A1 (en) 2023-07-06
JP7181185B2 (ja) 2022-11-30
CN116869983A (zh) 2023-10-13
AU2017326519B2 (en) 2023-03-16
RU2019107764A3 (enExample) 2021-01-15
RU2019107764A (ru) 2020-10-16
CA3036989A1 (en) 2018-03-22
KR20240005122A (ko) 2024-01-11
AU2017326519A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
US20050085446A1 (en) Fluoroquinolone formulations and methods of making and using the same
BRPI0921705B1 (pt) composição farmacêutica antimicrobiana e seu uso
US20150238448A1 (en) Formulation of radioprotective alpha, beta unsaturated aryl sulfones
RS49902B (sr) PREPARATI ZA TRETIRANJE I PREVENCIJU ARTERIJSKE TROMBOZE I KORIŠĆENJE INHIBITORA FAKTORA Xa SAMOG ILI U KOMBINACIJI SA PLATELETNIM ANTIAGREGACIONIM AGENSOM
CA2679919A1 (en) Compositions and methods for delivery of anti-cancer agents
US20070049552A1 (en) Fluoroquinolone formulations and methods of making and using the same
JP7597778B2 (ja) シクロデキストリン及びブスルファンを含有する組成物
AU2025204233A1 (en) Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
CN116490211A (zh) 眼用组合物
RU2772384C9 (ru) Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина
RU2772384C2 (ru) Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина
JP6748339B2 (ja) フィナフロキサシンおよびトリスを含む組成物
CN120529922A (zh) 肽药物偶联物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination